Bayer's Faith In Pharma Pipeline Paying Off
Positive News For Nubeqa and Kerendia
Executive Summary
The German major has presented the latest developments in the ongoing transformation of its pharmaceuticals business, starting with the prostate cancer therapy Nubeqa which Bayer believes will be a €3bn drug, way up on its earlier estimate of €1bn.
You may also be interested in...
No Slowdown From Bayer On Business Development Front
“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.